Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

[Forsøg med enhed, der ikke er godkendt eller godkendt af den amerikanske FDA] (ALARION EV)

26. juni 2026 opdateret af: AtaCor Medical, Inc.

The ALARION EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of this pivotal study is to generate evidence of safety and effectiveness to apply for regulatory approvals for commercialization of the Parasternal EV-ICD System.

The objective of the study is to demonstrate safety and effectiveness of the Parasternal EV-ICD System through 6-months.

Studieoversigt

Detaljeret beskrivelse

The primary safety endpoint is Freedom from Major Adverse Device Effects (MADEs) through 6 months. The primary effectiveness endpoint is Defibrillation Performance: Successful induced ventricular arrhythmia (IVA) test in the final system configuration.

Up to 40 Investigational Sites Worldwide will participate with up to 280 subjects enrolled in the study. At least 50% of subjects will be enrolled at sites in the United States.

Subjects meeting indications for ICD therapy who do not require permanent bradycardia pacing will be eligible for participation. Eligible Subjects will receive an Atala™ lead connected to an EV-ICD Pulse Generator positioned in a left pectoral or left lateral location. The Parasternal EV-ICD System will be tested to verify appropriate sensing and defibrillation.

Starting at 6 months, Subjects will be followed every 6 months until the study is closed. The study is expected to be ongoing for a minimum of 2.5 years from the date of first enrollment. Endpoints will be analyzed and summarized in a final study report after all active Subjects have completed the 6-month visit.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

280

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Sarah Hase, BS, CCRA
  • Telefonnummer: +1 949-545-9820
  • E-mail: sarah@atacor.com

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. At least 18 years old
  2. Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines or ESC guidelines

Exclusion Criteria:

  1. Patients who cannot read or write
  2. Expected survival < 1 year
  3. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
  4. Participation in any concurrent clinical study without prior approval from the Sponsor
  5. Inability or unwillingness to provide informed consent to participate in the study
  6. Any known circumstances which may prevent the completion of protocol testing and data collection through the 6-month follow-up visit
  7. Circumstances that may prevent data collection or completion of specified follow-up visits
  8. Allergies to any device materials listed in the Instructions for Use (IFU)
  9. Contraindication for temporary suspension of oral/systemic anticoagulation
  10. Known history of lung disease with FEV1 < 1.0 Liter

    Device Related:

  11. Implanted with or planned implantation of any device which delivers current in the body that may interfere with therapy delivery, including, but not limited to a pacemaker, LVAD or neurostimulator
  12. Implanted with a subcutaneous ICD lead, subcutaneous coils/arrays, epicardial patches or epicardial pace/sense leads
  13. Any known need for MRI prior to approval of MRI conditional labeling

    Anatomy Related:

  14. Known structural abnormalities of the heart that may increase risk of the Parasternal EV-ICD System procedure
  15. Known obstructed or restricted pathway into the mediastinum for the Atala™ lead
  16. Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium, including sternotomy of any type
  17. Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis)
  18. History of thoracic radiation therapy or other medical treatments/conditions which may complicate the Parasternal EV-ICD System implant procedure
  19. Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax
  20. Surgically corrected congenital heart disease (not including catheter-based procedures)

    Cardiac Related:

  21. Indication for permanent bradycardia pacing or cardiac resynchronization therapy
  22. Decompensated heart failure
  23. Currently on inotropic therapy
  24. Known history of pericardial disease, pericarditis or mediastinitis
  25. Risk factors associated with defibrillation testing:

    • Severe aortic stenosis
    • Current Intracardiac LA or LV thrombus
    • Severe proximal three-vessel or left main coronary artery disease without revascularization
    • Hemodynamic instability
    • Unstable angina
    • Recent stroke or transient ischemic attack (within the last 3 months)
    • Known inadequate external defibrillation
    • LVEF < 20% (most recent assessment; must be within 180 days of consent)
    • LVEDD >70 mm (most recent assessment; must be within 180 days of consent)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Parasternal EV-ICD System
Subjects implanted with the Atala™ lead and EV-ICD pulse generator
Subjects will receive the Atala™ lead and EV-ICD pulse generator being evaluated in the study.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Freedom from MADEs
Tidsramme: Through 6 months post-implant
Freedom from Major Adverse Device Effects (MADEs)
Through 6 months post-implant
Successful IVA Test
Tidsramme: At the time of procedure and up to 60 days post-implant
Successful induced ventricular arrhythmia (IVA) test in the final system configuration
At the time of procedure and up to 60 days post-implant

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. juli 2026

Primær færdiggørelse (Anslået)

31. august 2027

Studieafslutning (Anslået)

31. december 2028

Datoer for studieregistrering

Først indsendt

5. januar 2026

Først indsendt, der opfyldte QC-kriterier

6. januar 2026

Først opslået (Faktiske)

7. januar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

26. juni 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Ventrikulær fibrillation

Kliniske forsøg med Atala™ lead and EV-ICD Pulse Generator

3
Abonner